Gene silencing by chemically modified siRNAs

New Biotechnology

Volumn 30, Issue 3, 2013, Pages 302-307

  Engels, Joachim W ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICALLY MODIFIED; DRUG DESIGN STRATEGIES; GENE SILENCING; GOLD STANDARDS; IMMUNOGENICITY; RNA INTERFERENCE; TARGET PROTEINS; THERAPEUTIC PARADIGMS;

CHEMICAL MODIFICATION; GENE THERAPY; GENETIC ENGINEERING;

RNA;

ALPHA INTERFERON; DICER; INTERLEUKIN 6; LENTIVIRUS VECTOR; MESSENGER RNA; NUCLEOTIDE; PATTERN RECOGNITION RECEPTOR; RETROVIRUS VECTOR; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; FUNCTIONAL GENOMICS; GENE SILENCING; GENE TARGETING; GENETIC RESISTANCE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RNA CLEAVAGE; RNA INTERFERENCE; RNA STABILITY; RNA SYNTHESIS; THERMOSTABILITY;

DRUG DESIGN; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84878111348     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.07.002     Document Type: Article

References (55)

1. Heermeier K., et al. Meeting review: ESF workshop on impact of nucleic acid chemistry on gene function analysis: antisense, aptamers, ribozymes and RNAi. Comp. Funct. Genomics 2002, 3:441-446.
2. Elbashir S., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-549.
3. Fire A.Z. Gene silencing by double-stranded RNA (Nobel lecture). Angew. Chem. Int. Ed. 2007, 46:6966-6984.
4. Mello C.C. Return to the RNAi world: rethinking gene expression and evolution (Nobel lecture). Angew. Chem. Int. Ed. 2007, 46:6985-6994.
5. Dorsett Y., Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 2004, 3:318-329.
6. Fire A.Z., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
7. Li Z., Rana T.M. Molecular mechanism of RNA-triggered gene silencing machineries. Acc. Chem. Res. 2012, 10.1021/ar200253u.
8. Wang Y., et al. Structure of the guide-strand-containing argonaute silencing complex. Nature 2008, 456:209-213.
9. Peacock H., et al. Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem. 2011, 76:7295-7300.
10. Simpson K.J., et al. Comparative high-throughput RNAi screening methodologies in C. elegans and mammalian cells. New Biotechnol. 2012, 29:459-470.
11. Brummelkamp T.R., et al. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
12. Whitehurst A.W., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
13. Wang J., et al. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010, 12:492-503.
14. Bramsen J.B., Kjems J. Development of therapeutic-grade small interfering RNAs by chemical engineering. Methods Mol. Biol. (N. Y., U.S.A.) 2011, 721:77-103.
15. Rossi K., et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 2005, 23:222-226.
16. Siolas D., et al. Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. 2005, 23:227-231.
17. Reynolds A., et al. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22:326-330.
18. Khvorova A., et al. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115:209-216.
19. Schwarz D.S., et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 15:199-208.
20. Rose S.D., et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 2005, 33:4140-4156.
21. Sledz C.A., et al. Activation of the interferon system by short interfering RNAs. Nat. Cell Biol. 2003, 5:834-839.
22. Jackson A.L., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21:635-637.
23. Czauderna F., et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003, 31:2705-2716.
24. Wilson C., Keefe A.D. Building oligonucleotide therapeutics using non natural chemistries. Curr. Opin. Chem. Biol. 2006, 10:607-614.
25. Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr. Med. Chem. 2005, 12:2193-2214.
26. Detzer A., Sczakiel G. Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery. Curr. Top. Med. Chem. 2009, 9:1109-1116.
27. Chiu Y.L., Rana T.M. siRNA function in RNAi: a chemical modification analysis. RNA 2003, 9:1034-1048.
28. Prakash T.P., et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 2005, 48:4247-4253.
29. Soutschek J., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
30. Layzer J.M. In vivo activity of nuclease-resistant siRNAs. RNA 2004, 10:766-771.
31. Odadzic D., Bramsen J.B. Synthesis of 2'-O-modified adenosine building blocks and application for RNA interference. Bioorg. Med. Chem. 2008, 16:518-529.
32. Engels J.W., et al. Chemical synthesis of 2'-O-alkylated siRNAs. Methods Mol. Biol. 2010, 623:155-170. (RNA interference).
33. Brzezinska J., et al. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg. Med. Chem. 2012, 20:1594-1606.
34. Bramsen J.B., et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009, 37:2867-2881.
35. Petersen M., Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 2003, 21:74-81.
36. Grunweller A., et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 2003, 31:3185-3193.
37. Glud S.Z., et al. Naked siLNA mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 2009, 19:163-168.
38. Hornung V., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11:263-270.
39. Langkjaer N., et al. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 2009, 17:5420-5425.
40. Bramsen J.B. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 2010, 38:5761-5773.
41. Allerson C., et al. Fully 2-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 2005, 48:901-904.
42. Tsui N.B., et al. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 2002, 48:1647-1653.
43. Hickerson R.P. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008, 18:345-354.
44. Turner J.J., et al. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. Biosyst. 2007, 3:43-50.
45. Volkov A.A., et al. Selective protection of nuclease sensitive sites in siRNA prolongs silencing effect. Oligonucleotides 2009, 19:191-202.
46. Minks M.A., et al. Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J. Biol. Chem. 1979, 254:10180-10183.
47. Kariko K., et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 2004, 172:6545-6549.
48. Sioud M., et al. Deciphering the code of innate immunity recognition of siRNAs. Methods Mol. Biol. 2009, 487:41-59.
49. Kim D.H., et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 2004, 22:321-325.
50. Morrissey D.V., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
51. Du Q., et al. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 2005, 33:1671-1677.
52. Dahlgren C., et al. Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res. 2008, 36:e53.
53. Doench J.G., et al. siRNAs can function as miRNAs. Genes Dev. 2003, 17:438-442.
54. Jackson A.L., et al. Position-specific chemical modification of siRNAs reduces off-target transcript silencing. RNA 2006, 12:1197-1205.
55. Chen P.Y., et al. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14:263-274.